Search clinical trials for: ASP2151

Total 106 results

Maruho Co., Ltd.

Completed

Phase III Study of ASP2151 in Herpes Simplex Patients

Herpes Simplex

Japan
Astellas Pharma Inc

Completed

Study to Evaluate the Safety and Pharmacokinetics of ASP2151 in Healthy Non-elderly and Elderly Subjects

Healthy Subjects

Japan
Astellas Pharma Europe Ltd.

Completed

Study to Evaluate the Safety and Pharmacokinetics of Single Doses of ASP2151 in Healthy Male Subjects and the Effects of Food

Herpes Zoster | Herpes Genitalis

France
Maruho Co., Ltd.

Completed

Open-label Study of ASP2151 in Herpes Simplex Patients

Herpes Simplex

Japan
Astellas Pharma Global Development, Inc.

Completed

Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial

Acute Myeloid Leukemia | Advanced Solid Tumors

United States
Astellas Pharma Inc
FibroGen

Completed

A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia

Chronic Kidney Disease

Japan
Astellas Pharma Inc
FibroGen

Completed

A Study of Intermittent Oral Dosing of ASP1517 in Erythropoieses Stimulating Agent (ESA)-Naive Hemodialysis Chronic Kidney Disease Patients With Anemia

ESA-naive Hemodialysis Chronic Kidney Disease Patients With Anemia

Japan
Astellas Pharma Inc
FibroGen

Completed

A Study of Intermittent Oral Dosing of ASP1517 in Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia

Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia

Japan
Astellas Pharma Global Development, Inc.

Recruiting

A Study of ASP2138 in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, Pancreatic Cancer

Pancreatic Adenocarcinoma | Gastric Adenocarcinoma | Gastroesophageal Junction (GEJ) Adenocarcinoma

United States, Japan, Korea, Republic of
Astellas Pharma Inc
FibroGen

Completed

A Food Effect Study to Evaluate the Pharmacokinetics of ASP1517

Healthy Subjects

Japan
Maruho Co., Ltd.

Completed

Phase III Study of ASP2151 in Herpes Zoster Patients

Herpes Zoster

Japan
Astellas Pharma Global Development, Inc.

Completed

A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of ASP2215

Healthy | Hepatic Impairment

United States
Astellas Pharma Inc

Completed

A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes

Herpes Genitalis

United States
Astellas Pharma Inc

Terminated

Study Comparing the Safety of ASP2151 to Valacyclovir and Placebo in Healthy Volunteers

Safety of ASP2151

United States
Astellas Pharma Inc
FibroGen

Completed

A Long Term Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia Converted From Erythropoieses Stimulating Agent (ESA) Treatment

Hemodialysis Patients With Renal Anemia

Japan
Astellas Pharma Inc

Completed

Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML)

Japan
Etan Orgel
Astellas Pharma Global Development, Inc.

No longer available

Individual Patient Expanded Access Gilteritinib (ASP2215)

AML

United States
Astellas Pharma Inc

Completed

ASP1517 Phase 2 Clinical Trial - Double-Blind Study of ASP1517 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis-

Anemia in Chronic Kidney Disease Patients Not on Dialysis

Japan
Astellas Pharma Global Development, Inc.
FibroGen

Completed

A Study to Assess the Relative Bioavailability of Roxadustat Following a Single Dose of Pediatric Azo Dye-free Tablet Formulation and Pediatric Azo Dye-free Mini-tablet Formulation Compared to a Single Dose of Azo Dye-containing Tablet Formulation in Healthy Adult Subjects

Healthy Adult Subjects

Germany
Astellas Pharma Inc

Completed

ASP1517 Pharmacokinetics Study in Anemia Patients on Hemodialysis

Anemia | Hemodialysis | Renal Impairment

Japan
Astellas Pharma Inc

Completed

Dose-finding Study of ASP2151 in Subjects With Herpes Zoster

Herpes Zoster

Japan
Astellas Pharma Global Development, Inc.

Completed

A Study to Investigate the Effect of Severe Renal Impairment on Gilteritinib Compared to Healthy Participants With Normal Renal Function

Renal Impaired | Gilteritinib | Normal Renal Function | Pharmacokinetics of ASP2215

United States, Bulgaria
Astellas Pharma Europe B.V.
FibroGen

Completed

A Phase 1 Study of Roxadustat in Subjects With Different Degrees of Renal Function

Impaired Renal Function | Normal Renal Function

Germany, United Kingdom
Astellas Pharma Inc

Active, not recruiting

Post-marketing Surveillance of EVRENZO® Tablets (Roxadustat) in Patients With Renal Anemia

Renal Anemia

Japan
Astellas Pharma Inc
FibroGen

Completed

Pharmacokinetic Study of ASP1517 With Kremezin®

Healthy Volunteers

Japan
Maruho Europe Limited

Completed

Drug-Drug Interaction Study: ASP2151 and Ciclosporin

Healthy

United Kingdom
Astellas Pharma Global Development, Inc.

Completed

A Study to Assess the Relative Bioavailability of Gilteritinib Following a Single Dose of Gilteritinib Mini-tablet Oral Suspension and Gilteritinib Mini-tablets Compared to a Single Dose of Gilteritinib Tablet in Healthy Subjects

Healthy Volunteer

United States
Astellas Pharma Global Development, Inc.

Completed

Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors

Advanced Solid Tumors | Pharmacokinetics of 14C-labeled Gilteritinib

United States
Astellas Pharma Inc

Completed

Safety, Tolerability and Pharmacokinetic Study of ASP1517 in Healthy Non-elderly Male Volunteers

Healthy Volunteers

Japan
Astellas Pharma Inc
FibroGen

Completed

A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP1517 and Lanthanum Carbonate Hydrate

Healthy Subjects

Japan
Astellas Pharma Global Development, Inc.

No longer available

Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

Acute Myeloid Leukemia (AML) | FMS-like Tyrosine Kinase-3 (FLT3) Mutations

Australia, Italy, United Kingdom
Astellas Pharma Inc
FibroGen

Completed

A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia

Hemodialysis Chronic Kidney Disease Patients With Anemia

Japan
Astellas Pharma Europe B.V.
FibroGen

Completed

A Study to Investigate the Exposure and Safety and Tolerability of a Single Dose of FG-4592 in Subjects With Moderately Diminished Liver Function Compared to Those With Normal Liver Function

Hepatic Insufficiency | Healthy Subjects | PK of FG-4592

Bulgaria
Astellas Pharma Europe B.V.
FibroGen

Completed

A Study to Evaluate the Effects of Multiple Doses of FG-4592 on the Exposure, Safety and Tolerability and Effect of Warfarin in Healthy Subjects

Healthy Subjects | Pharmacokinetics of FG-4592

Germany
Astellas Pharma Global Development, Inc.

Completed

A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation

United States
Astellas Pharma Inc

Completed

A Study to Investigate the Effect of ASP1517 After Intermittent Oral Dosing in Dialysis Chronic Kidney Disease Patients With Anemia Compared With Darbepoetin as a Reference Drug

Renal Anemia Associated With Chronic Renal Failure (CRF)

Japan
Astellas Pharma Global Development, Inc.

Completed

A Phase I Study to Compare 3 Different Strengths of an Extended Release Formulation of ASP015K to an Immediate Release Formulation of ASP015K

Healthy Volunteers | Pharmacokinetics of ASP015K | Food Effect

United States
Astellas Pharma Global Development, Inc.

Recruiting

A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease

Chronic Kidney Disease | Renal Anemia

Romania, Spain, Belgium, Germany, Norway, Slovakia, Denmark
Astellas Pharma Inc
FibroGen

Completed

A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia

Chronic Kidney Disease

Japan
Astellas Pharma Europe B.V.
FibroGen

Completed

A Study to Evaluate the Dose-proportionality and Effects of FG-4592 in Healthy Young and Elderly Male and Female Subjects

Healthy Subjects | PK for FG-4592

Germany
FibroGen
AstraZeneca; Astellas Pharma Inc

Terminated

Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden

Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)

United States, Australia, Belgium, Germany, Israel, Italy, Korea, Republic of, Russian Federation, Spain, United Kingdom, France, Turkey, Canada, Denmark, India, Poland
Stichting Hemato-Oncologie voor Volwassenen Nederland
Astellas Pharma Global Development, Inc.; Deutsch-Österreichische Studiengruppe...

Active, not recruiting

A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML)

Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts-2

Netherlands, Belgium, Germany, Switzerland, Australia, Finland, Norway, Sweden, Austria, France, Ireland, Lithuania, Luxembourg, Spain
Astellas Pharma Inc

Completed

Pharmacokinetics Study in Patients With Impaired Renal Function and Subjects With Normal Renal Function

Patients With Impaired Renal Function

Japan
Astellas Pharma Global Development, Inc.
Janssen Biotech, Inc.

Completed

A Study to Assess the Relative Bioavailability Between Two ASP015K Tablets and the Food Effect of a New Tablet in Healthy Adult Subjects

Healthy Subjects | Bioavailability of ASP015K | Pharmacokinetics of ASP015K | Food Effect of ASP015K

United States
Astellas Pharma Global Development, Inc.
Merck Sharp & Dohme LLC

Completed

A Study of ASP1951 in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States, Korea, Republic of, Canada, Taiwan
Astellas Pharma Inc

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K

Healthy Subjects | Pharmacodynamics | Pharmacokinetics of ASP015K

United States
Maruho Europe Limited

Completed

Drug-Drug Interaction Study: ASP2151 and Midazolam

Healthy

United Kingdom
Maruho Europe Limited

Completed

Drug-Drug Interaction Study: ASP2151 and Montelukast

Healthy

United Kingdom
Astellas Pharma Inc

Completed

A Single Oral Dose Study of ASP015K in Healthy Volunteers Assessing the Relative Bioavailability Across Three Tablet Strengths From a New Formulation of ASP015K

Healthy Subjects | Bioavailability of ASP015K | Pharmacokinetics of ASP015K

United States
FibroGen
AstraZeneca; Astellas Pharma Europe B.V.

Completed

Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants (Himalayas)

Anemia in Incident Dialysis Patients

Russian Federation, Bulgaria, Thailand, United States, Argentina, Chile, Colombia, Korea, Republic of, Latvia, Malaysia, Mexico, Poland, Romania, Taiwan, Ukraine

3

Subscribe